Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Idebenone evaluated in Huntington's disease

Sep. 20, 1996

Generic clonazepam approved

Sep. 20, 1996

Forest prepares NDA submission for antidepressant

Sep. 20, 1996

Hoechst Marion Roussel reports new antidepressants

Sep. 20, 1996

Fluphenazine ANDA approval

Sep. 20, 1996

New dopamine D4 receptor antagonists from Taisho and Nihon Nohyaku

Sep. 20, 1996

Anxiolytic/antidepressant approved in Japan

Sep. 20, 1996

Mitochondrial benzodiazepine receptor (MBR) ligands as potential anxiolytics

Sep. 20, 1996

Glaxo Wellcome identifies potential anxiolytic agents

Sep. 20, 1996

New CNS agents from American Cyanamid

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...